CATALOGO DEI PRODOTTI DELLA RICERCA

SCAFFIDI, Luigi
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 1.421
AS - Asia 1.176
EU - Europa 1.023
SA - Sud America 191
AF - Africa 24
OC - Oceania 20
Continente sconosciuto - Info sul continente non disponibili 3
AN - Antartide 1
Totale 3.859
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 1.398
CN - Cina 441
SG - Singapore 419
GB - Regno Unito 257
BR - Brasile 175
HK - Hong Kong 164
RU - Federazione Russa 128
IT - Italia 126
DE - Germania 114
SE - Svezia 105
FR - Francia 104
IE - Irlanda 90
KR - Corea 37
VN - Vietnam 34
FI - Finlandia 33
AU - Australia 19
IN - India 18
CA - Canada 12
PL - Polonia 11
TR - Turchia 10
ID - Indonesia 9
NL - Olanda 9
AT - Austria 8
JP - Giappone 8
MX - Messico 8
UA - Ucraina 8
AR - Argentina 6
BD - Bangladesh 6
BE - Belgio 6
IQ - Iraq 5
TG - Togo 5
CG - Congo 4
DZ - Algeria 4
CO - Colombia 3
EU - Europa 3
UZ - Uzbekistan 3
AE - Emirati Arabi Uniti 2
AZ - Azerbaigian 2
BY - Bielorussia 2
CH - Svizzera 2
CL - Cile 2
CZ - Repubblica Ceca 2
EC - Ecuador 2
ES - Italia 2
LV - Lettonia 2
MA - Marocco 2
NO - Norvegia 2
PK - Pakistan 2
RO - Romania 2
SA - Arabia Saudita 2
SY - Repubblica araba siriana 2
TN - Tunisia 2
TW - Taiwan 2
ZA - Sudafrica 2
AL - Albania 1
AM - Armenia 1
AQ - Antartide 1
BA - Bosnia-Erzegovina 1
BG - Bulgaria 1
BH - Bahrain 1
CI - Costa d'Avorio 1
CR - Costa Rica 1
CY - Cipro 1
DK - Danimarca 1
ET - Etiopia 1
GE - Georgia 1
GR - Grecia 1
IR - Iran 1
JM - Giamaica 1
JO - Giordania 1
KH - Cambogia 1
LB - Libano 1
LT - Lituania 1
LY - Libia 1
MY - Malesia 1
NG - Nigeria 1
NI - Nicaragua 1
NP - Nepal 1
NZ - Nuova Zelanda 1
PE - Perù 1
PT - Portogallo 1
RS - Serbia 1
SI - Slovenia 1
SM - San Marino 1
UG - Uganda 1
UY - Uruguay 1
VE - Venezuela 1
Totale 3.859
Salva come PNG Salva come JPEG
Città #
Chandler 293
Southend 229
Dallas 211
Singapore 175
Hong Kong 164
Beijing 122
Dublin 90
Woodbridge 83
Ashburn 63
Ann Arbor 48
Wilmington 41
Lawrence 40
Princeton 40
Jinan 34
Shenyang 33
The Dalles 32
New York 31
Jacksonville 30
Sindelfingen 26
Nanjing 25
Columbus 23
Munich 22
Verona 22
São Paulo 17
Los Angeles 15
Falls Church 13
Hebei 12
Helsinki 12
Nuremberg 12
Perth 12
San Francisco 12
Taiyuan 12
Tianjin 12
Zhengzhou 12
Changsha 10
Redmond 10
Santa Clara 10
Bologna 9
Dong Ket 9
Guangzhou 9
Ho Chi Minh City 9
Nanchang 9
Redwood City 9
Seattle 8
Seoul 8
Tokyo 8
Houston 7
Jakarta 7
Norwalk 7
Taizhou 7
Brussels 6
Chengdu 6
Council Bluffs 6
Haikou 6
Kent 6
Ningbo 6
Rio de Janeiro 6
Warsaw 6
Düsseldorf 5
Lomé 5
London 5
Milan 5
Phoenix 5
Shanghai 5
Belo Horizonte 4
Bergamo 4
Boston 4
Brasília 4
Fairfield 4
Frankfurt am Main 4
Goiânia 4
Porto Alegre 4
Toronto 4
Turku 4
Washington 4
Boardman 3
Brazzaville 3
Canberra 3
Cento 3
Chennai 3
Delhi 3
Fremont 3
Fuzhou 3
Hangzhou 3
Jaú 3
Jiaxing 3
Kochi 3
Kolkata 3
Melbourne 3
Mexico City 3
Naples 3
Osasco 3
Palermo 3
Paris 3
Polska 3
Rome 3
Salvador 3
Tashkent 3
Vicenza 3
Wuhan 3
Totale 2.351
Salva come PNG Salva come JPEG
Nome #
CAL2 Monoclonal Antibody Is a Rapid and Sensitive Assay for the Detection of Calreticulin Mutations in Essential Thrombocythemia and May Provide Prognostic Informations 164
BCR-ABL fusion transcript b2a2 is associated with a higher risk of non-optimal early response in CP-CML patients treated with standard dose imatinib: a study from Gruppo Triveneto LMC. 157
Predictors for response to ruxolitinib in real-life: an observational independent study on 266 patients with myelofibrosis 153
Predictors for Response to Ruxolitinib in Real-Life: An Observational Independent Study on 408 Patients with Myelofibrosis 139
Predictors of stable deep molecular response in chronic phase chronic myeloid leukemia patients treated with dasatinib or nilotinib after imatinib failure 138
CAL2 monoclonal antibody is a rapid and sensitive assay for the detection of calreticulin mutations in essential thrombocythemia patients 118
Imatinib-treated chronic myeloid leukemia patients with discordant response between cytogenetic and molecular tests at 3 and 6 month time-points have a reduced probability of subsequent optimal response 115
Predictive factors of stable deep molecular response in chronic myeloid leukemia patients treated with imatinib standard dose: a study from the Gruppo Triveneto LMC. 115
Anaphylactic Reactions After Discontinuation of Hymenoptera Venom Immunotherapy: A Clonal Mast Cell Disorder Should Be Suspected 114
Combination of EUTOS score and 3-month BCR-ABL transcript level identifies a group of good-risk chronic myeloid leukemia patients with favorable response to frontline imatinib therapy 112
Regulative Loop between β-catenin and Protein Tyrosine Receptor Type γ in Chronic Myeloid Leukemia 112
Comparison of dasatinib and nilotinib as second-line therapy after imatinib failure in chronic phase chronic myeloid leukemia patients. 106
Real-life comparison of dasatinib and nilotinib as second-line therapy after imatinib failure for chronic phase CML 102
The serological prevalence of SARS-CoV-2 infection in patients with chronic myeloid leukemia is similar to that in the general population 101
Benefit-risk profile of cytoreductive drugs along with antiplatelet and antithrombotic therapy after transient ischemic attack or ischemic stroke in myeloproliferative neoplasms 98
SETD2 and histone H3 lysine 36 methylation deficiency in advanced systemic mastocytosis 97
Excellent outcomes of 2G-TKI therapy after imatinib failure in chronic phase CML patients 96
Baseline factors associated with response to ruxolitinib: an independent study on 408 patients with myelofibrosis 95
Digital PCR improves the quantitation of DMR and the selection of CML candidates to TKIs discontinuation 93
Prospective assessment of NGS-detectable mutations in CML patients with nonoptimal response: the NEXT-in-CML study 88
Arterial thrombosis in Philadelphia-negative myeloproliferative neoplasms predicts second cancer: a case-control study 88
Bosutinib in the real-life treatment of chronic myeloid leukemia patients aged $greater$65~years resistant/intolerant to previous tyrosine-kinase inhibitors 87
Efficacy and safety of ruxolitinib in intermediate-1 IPSS risk myelofibrosis patients: Results from an independent study 86
Cardiovascular toxicity in patients with chronic myeloid leukemia treated with second-generation tyrosine kinase inhibitors in the real-life practice: Identification of risk factors and the role of prophylaxis 85
Differences in presenting features, outcome and prognostic models in patients with primary myelofibrosis and post-polycythemia vera and/or post-essential thrombocythemia myelofibrosis treated with ruxolitinib. New perspective of the MYSEC-PM in a large multicenter study⁎ 82
A successful treatment-free remission is achievable also by chronic myeloid leukemia patients lacking optimal requirements 77
Arterial occlusive events in chronic myeloid leukemia patients treated with ponatinib in the real-life practice are predicted by the Systematic Coronary Risk Evaluation (SCORE) chart 74
Imatinib and polypharmacy in very old patients with chronic myeloid leukemia: effects on response rate, toxicity and outcome 73
Epidemiology, outcome, and risk factors for infectious complications in myelofibrosis patients receiving ruxolitinib: A multicenter study on 446 patients 70
Management of Chronic Myeloid Leukemia in Advanced Phase 67
Impact of comorbidities and body mass index in patients with myelofibrosis treated with ruxolitinib 63
Life after ruxolitinib: Reasons for discontinuation, impact of disease phase, and outcomes in 218 patients with myelofibrosis 63
Safety and efficacy of switching from branded to generic imatinib in chronic phase chronic myeloid leukemia patients treated in Italy 62
Favorable outcome of chronic myeloid leukemia co-expressing e13a2 and e14a2 transcripts, treated with nilotinib 62
Second primary malignancy in myelofibrosis patients treated with ruxolitinib 61
BCR::ABL1 levels at first month after TKI discontinuation predict subsequent maintenance of treatment‐free remission: A study from the “GRUPPO TRIVENETO LMC” 55
Deferasirox in the management of iron overload in patients with myelofibrosis treated with ruxolitinib: The multicentre retrospective {RUX}-{IOL} study 53
Second cancers in MPN: Survival analysis from an international study 44
Renin angiotensin system inhibitors reduce the incidence of arterial thrombotic events in patients with hypertension and chronic myeloid leukemia treated with second- or third-generation tyrosine kinase inhibitors 43
Long-term mortality rate for cardiovascular disease in 656 chronic myeloid leukaemia patients treated with second- and third-generation tyrosine kinase inhibitors 41
Low low-density lipoprotein (LDL), cholesterol and triglycerides plasma levels are associated with reduced risk of arterial occlusive events in chronic myeloid leukemia patients treated with ponatinib in the real-life. A Campus CML study 39
The new Systematic Coronary Risk Evaluation (SCORE2 and SCORE2-OP) estimates the risk of arterial occlusive events in chronic myeloid leukemia patients treated with nilotinib or ponatinib 38
Second cancer in Philadelphia negative myeloproliferative neoplasms (MPN-K). A nested case-control study 36
Recurrent arterial occlusive events in patients with chronic myeloid leukemia treated with second- and third-generation tyrosine kinase inhibitors and role of secondary prevention 36
Successful Preservation of Native BCR::ABL1 in Chronic Myeloid Leukemia Primary Leukocytes Reveals a Reduced Kinase Activity 31
Ropeginterferon phase 2 randomized study in low-risk polycythemia vera: 5-year drug survival and efficacy outcomes 28
Ropeginterferon versus Standard Therapy for Low-Risk Patients with Polycythemia Vera 28
Incidence of blast phase in myelofibrosis patients according to anemia severity at ruxolitinib start and during therapy 27
Refined diagnostic criteria for bone marrow mastocytosis: a proposal of the European competence network on mastocytosis 25
Ruxolitinib in cytopenic myelofibrosis: Response, toxicity, drug discontinuation, and outcome 15
Totale 3.952
Salva come PNG Salva come JPEG
Categoria #
all - tutte 17.622
article - articoli 14.076
book - libri 0
conference - conferenze 3.546
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 35.244
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021166 0 0 11 27 46 28 1 2 3 3 22 23
2021/2022308 31 80 16 40 10 10 6 14 11 2 14 74
2022/2023711 42 82 69 121 72 167 3 41 77 11 14 12
2023/2024398 11 36 19 52 33 32 14 18 10 41 102 30
2024/20251.078 46 57 39 187 60 39 83 76 137 67 97 190
2025/2026536 217 188 131 0 0 0 0 0 0 0 0 0
Totale 3.952